Logo image of PIII

P3 HEALTH PARTNERS INC (PIII) Stock Fundamental Analysis

NASDAQ:PIII - Nasdaq - US7444132044 - Common Stock - Currency: USD

6.37  +0.21 (+3.41%)

Fundamental Rating

1

Taking everything into account, PIII scores 1 out of 10 in our fundamental rating. PIII was compared to 103 industry peers in the Health Care Providers & Services industry. PIII may be in some trouble as it scores bad on both profitability and health. PIII is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

PIII had negative earnings in the past year.
In the past year PIII has reported a negative cash flow from operations.
PIII had negative earnings in each of the past 5 years.
PIII had a negative operating cash flow in each of the past 5 years.
PIII Yearly Net Income VS EBIT VS OCF VS FCFPIII Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

The Return On Assets of PIII (-17.56%) is worse than 83.50% of its industry peers.
With a Return On Equity value of -217.60%, PIII is not doing good in the industry: 78.64% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -17.56%
ROE -217.6%
ROIC N/A
ROA(3y)-18.29%
ROA(5y)-20.52%
ROE(3y)-1599.17%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PIII Yearly ROA, ROE, ROICPIII Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

1.3 Margins

PIII does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PIII Yearly Profit, Operating, Gross MarginsPIII Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -10 -20 -30 -40 -50

More info and screens

0

2. Health

2.1 Basic Checks

PIII does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for PIII has been increased compared to 1 year ago.
PIII has more shares outstanding than it did 5 years ago.
PIII has a worse debt/assets ratio than last year.
PIII Yearly Shares OutstandingPIII Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 1M 2M 3M
PIII Yearly Total Debt VS Total AssetsPIII Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

Based on the Altman-Z score of -0.78, we must say that PIII is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of PIII (-0.78) is worse than 82.52% of its industry peers.
PIII has a Debt/Equity ratio of 1.69. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 1.69, PIII is not doing good in the industry: 72.82% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.69
Debt/FCF N/A
Altman-Z -0.78
ROIC/WACCN/A
WACC10.43%
PIII Yearly LT Debt VS Equity VS FCFPIII Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 0.38 indicates that PIII may have some problems paying its short term obligations.
PIII has a worse Current ratio (0.38) than 93.20% of its industry peers.
A Quick Ratio of 0.38 indicates that PIII may have some problems paying its short term obligations.
With a Quick ratio value of 0.38, PIII is not doing good in the industry: 92.23% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.38
Quick Ratio 0.38
PIII Yearly Current Assets VS Current LiabilitesPIII Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

5

3. Growth

3.1 Past

PIII shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -51.80%.
PIII shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 9.78%.
The Revenue has been growing by 59.38% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-51.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.5%
Revenue 1Y (TTM)9.78%
Revenue growth 3Y33.03%
Revenue growth 5Y59.38%
Sales Q2Q%-3.93%

3.2 Future

Based on estimates for the next years, PIII will show a very strong growth in Earnings Per Share. The EPS will grow by 21.45% on average per year.
Based on estimates for the next years, PIII will show a small growth in Revenue. The Revenue will grow by 1.39% on average per year.
EPS Next Y48.78%
EPS Next 2Y27.38%
EPS Next 3Y21.45%
EPS Next 5YN/A
Revenue Next Year-5.92%
Revenue Next 2Y-0.13%
Revenue Next 3Y1.39%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
PIII Yearly Revenue VS EstimatesPIII Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 500M 1B 1.5B
PIII Yearly EPS VS EstimatesPIII Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -50 -100 -150 -200 -250

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PIII. In the last year negative earnings were reported.
Also next year PIII is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PIII Price Earnings VS Forward Price EarningsPIII Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PIII Per share dataPIII EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 50 -50 100 150 200

4.3 Compensation for Growth

PIII's earnings are expected to grow with 21.45% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.38%
EPS Next 3Y21.45%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PIII!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

P3 HEALTH PARTNERS INC

NASDAQ:PIII (6/27/2025, 8:00:00 PM)

6.37

+0.21 (+3.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)05-15 2025-05-15/amc
Earnings (Next)08-05 2025-08-05
Inst Owners11.57%
Inst Owner Change-18.57%
Ins Owners3.68%
Ins Owner Change0%
Market Cap45.80M
Analysts80
Price Target26.52 (316.33%)
Short Float %4.3%
Short Ratio0.77
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-167.67%
Min EPS beat(2)-366.28%
Max EPS beat(2)30.94%
EPS beat(4)1
Avg EPS beat(4)-267.5%
Min EPS beat(4)-658.17%
Max EPS beat(4)30.94%
EPS beat(8)3
Avg EPS beat(8)-141.81%
EPS beat(12)5
Avg EPS beat(12)-99.64%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-0.88%
Min Revenue beat(2)-3.87%
Max Revenue beat(2)2.11%
Revenue beat(4)1
Avg Revenue beat(4)-1.85%
Min Revenue beat(4)-3.87%
Max Revenue beat(4)2.11%
Revenue beat(8)4
Avg Revenue beat(8)1.92%
Revenue beat(12)7
Avg Revenue beat(12)2.33%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-5.45%
PT rev (3m)3366.67%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-7109.47%
EPS NY rev (1m)3.65%
EPS NY rev (3m)-6044.74%
Revenue NQ rev (1m)0.62%
Revenue NQ rev (3m)-5.04%
Revenue NY rev (1m)0.77%
Revenue NY rev (3m)-2.3%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.03
P/FCF N/A
P/OCF N/A
P/B 0.72
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-44.78
EYN/A
EPS(NY)-17.55
Fwd EYN/A
FCF(TTM)-17.19
FCFYN/A
OCF(TTM)-17.19
OCFYN/A
SpS206.56
BVpS8.8
TBVpS-68.24
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -17.56%
ROE -217.6%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-18.29%
ROA(5y)-20.52%
ROE(3y)-1599.17%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover1.89
Health
Industry RankSector Rank
Debt/Equity 1.69
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.38
Quick Ratio 0.38
Altman-Z -0.78
F-Score3
WACC10.43%
ROIC/WACCN/A
Cap/Depr(3y)1.55%
Cap/Depr(5y)81.99%
Cap/Sales(3y)0.12%
Cap/Sales(5y)0.3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-51.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.5%
EPS Next Y48.78%
EPS Next 2Y27.38%
EPS Next 3Y21.45%
EPS Next 5YN/A
Revenue 1Y (TTM)9.78%
Revenue growth 3Y33.03%
Revenue growth 5Y59.38%
Sales Q2Q%-3.93%
Revenue Next Year-5.92%
Revenue Next 2Y-0.13%
Revenue Next 3Y1.39%
Revenue Next 5YN/A
EBIT growth 1Y-88.38%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year85.32%
EBIT Next 3Y27.3%
EBIT Next 5YN/A
FCF growth 1Y0.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1.32%
OCF growth 3YN/A
OCF growth 5YN/A